Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | The importance of biomarkers in treating melanoma patients

Christian Blank • 21 Sep 2017
ESMO 2017
Melanoma

With the vast range of options now available to treat melanoma, it is important that we identify biomarkers which can help us to determine the most suitable treatment for each patient. Christian Blank, MD, PhD, from the Netherlands Cancer Institute, Amsterdam, Netherlands talks to us about his presentation on the topic of biomarkers, and discusses where future work in this field should focus. This presentation was recorded at the 2017 European Society for Medical Oncology (ESMO) held in Madrid, Spain.

More from Christian Blank

Neoadjuvant ipilimumab plus nivolumab in stage III melanoma
1:55
Neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Christian Blank • 16 Apr 2021
The future of adjuvant therapy in melanoma
1:44
The future of adjuvant therapy in melanoma
Christian Blank • 19 Apr 2021
Neoadjuvant IPI + NIVO in stage III melanoma: updates from OpACIN & OpACIN-neo
1:16
Neoadjuvant IPI + NIVO in stage III melanoma: updates from OpACIN & OpACIN-neo
Christian Blank • 19 Apr 2021
Predicting resistance to targeted therapies in melanoma
1:09
Predicting resistance to targeted therapies in melanoma
Christian Blank • 27 Sep 2019

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals